Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Pozzilli

Showing results (201-210 of 247) with videos related to

Pageof 25
Sort By:
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 15, 2025
Multiple sclerosis from onset to secondary progression: a 30-year Italian register studyAurora Zanghì, Massimiliano Copetti, Carlo Avolio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension studyRalf Gold, Douglas L Arnold, Amit Bar-Or, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 10, 2014
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsEmilio Portaccio, Angelo Ghezzi, Bahia Hakiki, et al.
Neurology|December 28, 2018
Unraveling treatment response in multiple sclerosis: A clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 5, 2018
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosisDoriana Landi, Paolo Ragonese, Luca Prosperini, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 27, 2024
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experienceSerena Ruggieri, Antonio Ianniello, Massimiliano Copetti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2016
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosisLuisa Pastò, Emilio Portaccio, Benedetta Goretti, et al.
Neurology|June 8, 2018
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched studyLuca Prosperini, Matteo Lucchini, Shalom Haggiag, et al.
BMC Neurology|June 3, 2014
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric studyChiara Pecori, Marta Giannini, Emilio Portaccio, et al.
Pageof 25

Showing results (201-210 of 247) with videos related to

Sort By:
Pageof 25
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 15, 2025
Multiple sclerosis from onset to secondary progression: a 30-year Italian register studyAurora Zanghì, Massimiliano Copetti, Carlo Avolio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension studyRalf Gold, Douglas L Arnold, Amit Bar-Or, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 10, 2014
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsEmilio Portaccio, Angelo Ghezzi, Bahia Hakiki, et al.
Neurology|December 28, 2018
Unraveling treatment response in multiple sclerosis: A clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 5, 2018
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosisDoriana Landi, Paolo Ragonese, Luca Prosperini, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 27, 2024
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experienceSerena Ruggieri, Antonio Ianniello, Massimiliano Copetti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2016
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosisLuisa Pastò, Emilio Portaccio, Benedetta Goretti, et al.
Neurology|June 8, 2018
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched studyLuca Prosperini, Matteo Lucchini, Shalom Haggiag, et al.
BMC Neurology|June 3, 2014
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric studyChiara Pecori, Marta Giannini, Emilio Portaccio, et al.
Pageof 25